<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<style>body{background-color:white;}</style>


</head>
<body>
<div id="nxammcrtrl" style="padding-left:0px;padding-right:0px;padding-top:10px;padding-bottom:10px;overflow-x:auto;overflow-y:auto;width:auto;height:auto;">
  <style>#nxammcrtrl table {
  font-family: system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji';
  -webkit-font-smoothing: antialiased;
  -moz-osx-font-smoothing: grayscale;
}

#nxammcrtrl thead, #nxammcrtrl tbody, #nxammcrtrl tfoot, #nxammcrtrl tr, #nxammcrtrl td, #nxammcrtrl th {
  border-style: none;
}

#nxammcrtrl p {
  margin: 0;
  padding: 0;
}

#nxammcrtrl .gt_table {
  display: table;
  border-collapse: collapse;
  line-height: normal;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 12px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #A8A8A8;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #A8A8A8;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

#nxammcrtrl .gt_caption {
  padding-top: 4px;
  padding-bottom: 4px;
}

#nxammcrtrl .gt_title {
  color: #333333;
  font-size: 125%;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

#nxammcrtrl .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 3px;
  padding-bottom: 5px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

#nxammcrtrl .gt_heading {
  background-color: #FFFFFF;
  text-align: center;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#nxammcrtrl .gt_bottom_border {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#nxammcrtrl .gt_col_headings {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#nxammcrtrl .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

#nxammcrtrl .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

#nxammcrtrl .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

#nxammcrtrl .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

#nxammcrtrl .gt_column_spanner {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 5px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

#nxammcrtrl .gt_spanner_row {
  border-bottom-style: hidden;
}

#nxammcrtrl .gt_group_heading {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  text-align: left;
}

#nxammcrtrl .gt_empty_group_heading {
  padding: 0.5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

#nxammcrtrl .gt_from_md > :first-child {
  margin-top: 0;
}

#nxammcrtrl .gt_from_md > :last-child {
  margin-bottom: 0;
}

#nxammcrtrl .gt_row {
  padding-top: 5px;
  padding-bottom: 5px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

#nxammcrtrl .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 5px;
  padding-right: 5px;
}

#nxammcrtrl .gt_stub_row_group {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 5px;
  padding-right: 5px;
  vertical-align: top;
}

#nxammcrtrl .gt_row_group_first td {
  border-top-width: 2px;
}

#nxammcrtrl .gt_row_group_first th {
  border-top-width: 2px;
}

#nxammcrtrl .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#nxammcrtrl .gt_first_summary_row {
  border-top-style: solid;
  border-top-color: #D3D3D3;
}

#nxammcrtrl .gt_first_summary_row.thick {
  border-top-width: 2px;
}

#nxammcrtrl .gt_last_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#nxammcrtrl .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#nxammcrtrl .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

#nxammcrtrl .gt_last_grand_summary_row_top {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-style: double;
  border-bottom-width: 6px;
  border-bottom-color: #D3D3D3;
}

#nxammcrtrl .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

#nxammcrtrl .gt_table_body {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#nxammcrtrl .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#nxammcrtrl .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
}

#nxammcrtrl .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#nxammcrtrl .gt_sourcenote {
  font-size: 90%;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
}

#nxammcrtrl .gt_left {
  text-align: left;
}

#nxammcrtrl .gt_center {
  text-align: center;
}

#nxammcrtrl .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

#nxammcrtrl .gt_font_normal {
  font-weight: normal;
}

#nxammcrtrl .gt_font_bold {
  font-weight: bold;
}

#nxammcrtrl .gt_font_italic {
  font-style: italic;
}

#nxammcrtrl .gt_super {
  font-size: 65%;
}

#nxammcrtrl .gt_footnote_marks {
  font-size: 75%;
  vertical-align: 0.4em;
  position: initial;
}

#nxammcrtrl .gt_asterisk {
  font-size: 100%;
  vertical-align: 0;
}

#nxammcrtrl .gt_indent_1 {
  text-indent: 5px;
}

#nxammcrtrl .gt_indent_2 {
  text-indent: 10px;
}

#nxammcrtrl .gt_indent_3 {
  text-indent: 15px;
}

#nxammcrtrl .gt_indent_4 {
  text-indent: 20px;
}

#nxammcrtrl .gt_indent_5 {
  text-indent: 25px;
}

#nxammcrtrl .katex-display {
  display: inline-flex !important;
  margin-bottom: 0.75em !important;
}

#nxammcrtrl div.Reactable > div.rt-table > div.rt-thead > div.rt-tr.rt-tr-group-header > div.rt-th-group:after {
  height: 0px !important;
}
</style>
  <table class="gt_table" data-quarto-disable-processing="false" data-quarto-bootstrap="false">
  <thead>
    <tr class="gt_heading">
      <td colspan="7" class="gt_heading gt_title gt_font_normal gt_bottom_border" style>Table 1: Baseline Characteristics by Drug Group</td>
    </tr>
    
    <tr class="gt_col_headings">
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1" scope="col" id="a::stub"></th>
      <th class="gt_col_heading gt_columns_bottom_border gt_right" rowspan="1" colspan="1" scope="col" id="Apixaban">Apixaban</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_right" rowspan="1" colspan="1" scope="col" id="Dabigatran">Dabigatran</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_right" rowspan="1" colspan="1" scope="col" id="Edoxaban">Edoxaban</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_right" rowspan="1" colspan="1" scope="col" id="Lisinopril">Lisinopril</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_right" rowspan="1" colspan="1" scope="col" id="Rivaroxaban">Rivaroxaban</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_right" rowspan="1" colspan="1" scope="col" id="Warfarin">Warfarin</th>
    </tr>
  </thead>
  <tbody class="gt_table_body">
    <tr><th id="stub_1_1" scope="row" class="gt_row gt_left gt_stub">Number of Cases</th>
<td headers="stub_1_1 Apixaban" class="gt_row gt_right">2677</td>
<td headers="stub_1_1 Dabigatran" class="gt_row gt_right">791</td>
<td headers="stub_1_1 Edoxaban" class="gt_row gt_right">6</td>
<td headers="stub_1_1 Lisinopril" class="gt_row gt_right">13014</td>
<td headers="stub_1_1 Rivaroxaban" class="gt_row gt_right">2964</td>
<td headers="stub_1_1 Warfarin" class="gt_row gt_right">8148</td></tr>
    <tr><th id="stub_1_2" scope="row" class="gt_row gt_left gt_stub">Observation Days (Person-days)</th>
<td headers="stub_1_2 Apixaban" class="gt_row gt_right">  781,337</td>
<td headers="stub_1_2 Dabigatran" class="gt_row gt_right">  262,464</td>
<td headers="stub_1_2 Edoxaban" class="gt_row gt_right">    2,018</td>
<td headers="stub_1_2 Lisinopril" class="gt_row gt_right">5,669,766</td>
<td headers="stub_1_2 Rivaroxaban" class="gt_row gt_right">  820,408</td>
<td headers="stub_1_2 Warfarin" class="gt_row gt_right">1,720,894</td></tr>
    <tr><th id="stub_1_3" scope="row" class="gt_row gt_left gt_stub">Number of Events</th>
<td headers="stub_1_3 Apixaban" class="gt_row gt_right">2802</td>
<td headers="stub_1_3 Dabigatran" class="gt_row gt_right">806</td>
<td headers="stub_1_3 Edoxaban" class="gt_row gt_right">6</td>
<td headers="stub_1_3 Lisinopril" class="gt_row gt_right">13776</td>
<td headers="stub_1_3 Rivaroxaban" class="gt_row gt_right">3081</td>
<td headers="stub_1_3 Warfarin" class="gt_row gt_right">8514</td></tr>
    <tr><th id="stub_1_4" scope="row" class="gt_row gt_left gt_stub">Sex: Male</th>
<td headers="stub_1_4 Apixaban" class="gt_row gt_right">1414 (52.8%)</td>
<td headers="stub_1_4 Dabigatran" class="gt_row gt_right">414 (52.3%)</td>
<td headers="stub_1_4 Edoxaban" class="gt_row gt_right">3 (50%)</td>
<td headers="stub_1_4 Lisinopril" class="gt_row gt_right">7322 (56.3%)</td>
<td headers="stub_1_4 Rivaroxaban" class="gt_row gt_right">1522 (51.3%)</td>
<td headers="stub_1_4 Warfarin" class="gt_row gt_right">4491 (55.1%)</td></tr>
    <tr><th id="stub_1_5" scope="row" class="gt_row gt_left gt_stub">Sex: Female</th>
<td headers="stub_1_5 Apixaban" class="gt_row gt_right">1263 (47.2%)</td>
<td headers="stub_1_5 Dabigatran" class="gt_row gt_right">377 (47.7%)</td>
<td headers="stub_1_5 Edoxaban" class="gt_row gt_right">3 (50%)</td>
<td headers="stub_1_5 Lisinopril" class="gt_row gt_right">5683 (43.7%)</td>
<td headers="stub_1_5 Rivaroxaban" class="gt_row gt_right">1441 (48.6%)</td>
<td headers="stub_1_5 Warfarin" class="gt_row gt_right">3650 (44.8%)</td></tr>
    <tr><th id="stub_1_6" scope="row" class="gt_row gt_left gt_stub">Sex: NA</th>
<td headers="stub_1_6 Apixaban" class="gt_row gt_right">NA</td>
<td headers="stub_1_6 Dabigatran" class="gt_row gt_right">NA</td>
<td headers="stub_1_6 Edoxaban" class="gt_row gt_right">NA</td>
<td headers="stub_1_6 Lisinopril" class="gt_row gt_right">9 (0.1%)</td>
<td headers="stub_1_6 Rivaroxaban" class="gt_row gt_right">1 (0%)</td>
<td headers="stub_1_6 Warfarin" class="gt_row gt_right">7 (0.1%)</td></tr>
    <tr><th id="stub_1_7" scope="row" class="gt_row gt_left gt_stub">Mean Age (SD)</th>
<td headers="stub_1_7 Apixaban" class="gt_row gt_right">73.73 (12.73)</td>
<td headers="stub_1_7 Dabigatran" class="gt_row gt_right">76.32 (10.47)</td>
<td headers="stub_1_7 Edoxaban" class="gt_row gt_right">57.33 (16.52)</td>
<td headers="stub_1_7 Lisinopril" class="gt_row gt_right">67.42 (14.2)</td>
<td headers="stub_1_7 Rivaroxaban" class="gt_row gt_right">70.9 (13.57)</td>
<td headers="stub_1_7 Warfarin" class="gt_row gt_right">68.45 (14.48)</td></tr>
    <tr><th id="stub_1_8" scope="row" class="gt_row gt_left gt_stub">Age 18-44 (n, %)</th>
<td headers="stub_1_8 Apixaban" class="gt_row gt_right">64 (2.4%)</td>
<td headers="stub_1_8 Dabigatran" class="gt_row gt_right">6 (0.8%)</td>
<td headers="stub_1_8 Edoxaban" class="gt_row gt_right">1 (16.7%)</td>
<td headers="stub_1_8 Lisinopril" class="gt_row gt_right">742 (5.7%)</td>
<td headers="stub_1_8 Rivaroxaban" class="gt_row gt_right">126 (4.3%)</td>
<td headers="stub_1_8 Warfarin" class="gt_row gt_right">497 (6.1%)</td></tr>
    <tr><th id="stub_1_9" scope="row" class="gt_row gt_left gt_stub">Age 45-64 (n, %)</th>
<td headers="stub_1_9 Apixaban" class="gt_row gt_right">609 (22.7%)</td>
<td headers="stub_1_9 Dabigatran" class="gt_row gt_right">113 (14.3%)</td>
<td headers="stub_1_9 Edoxaban" class="gt_row gt_right">3 (50%)</td>
<td headers="stub_1_9 Lisinopril" class="gt_row gt_right">5197 (39.9%)</td>
<td headers="stub_1_9 Rivaroxaban" class="gt_row gt_right">851 (28.7%)</td>
<td headers="stub_1_9 Warfarin" class="gt_row gt_right">2862 (35.1%)</td></tr>
    <tr><th id="stub_1_10" scope="row" class="gt_row gt_left gt_stub">Age 65-74 (n, %)</th>
<td headers="stub_1_10 Apixaban" class="gt_row gt_right">523 (19.5%)</td>
<td headers="stub_1_10 Dabigatran" class="gt_row gt_right">168 (21.2%)</td>
<td headers="stub_1_10 Edoxaban" class="gt_row gt_right">2 (33.3%)</td>
<td headers="stub_1_10 Lisinopril" class="gt_row gt_right">2437 (18.7%)</td>
<td headers="stub_1_10 Rivaroxaban" class="gt_row gt_right">612 (20.6%)</td>
<td headers="stub_1_10 Warfarin" class="gt_row gt_right">1530 (18.8%)</td></tr>
    <tr><th id="stub_1_11" scope="row" class="gt_row gt_left gt_stub">Age 75-84 (n, %)</th>
<td headers="stub_1_11 Apixaban" class="gt_row gt_right">928 (34.7%)</td>
<td headers="stub_1_11 Dabigatran" class="gt_row gt_right">324 (41%)</td>
<td headers="stub_1_11 Edoxaban" class="gt_row gt_right">NA</td>
<td headers="stub_1_11 Lisinopril" class="gt_row gt_right">3024 (23.2%)</td>
<td headers="stub_1_11 Rivaroxaban" class="gt_row gt_right">946 (31.9%)</td>
<td headers="stub_1_11 Warfarin" class="gt_row gt_right">2174 (26.7%)</td></tr>
    <tr><th id="stub_1_12" scope="row" class="gt_row gt_left gt_stub">Age 85+ (n, %)</th>
<td headers="stub_1_12 Apixaban" class="gt_row gt_right">556 (20.8%)</td>
<td headers="stub_1_12 Dabigatran" class="gt_row gt_right">180 (22.8%)</td>
<td headers="stub_1_12 Edoxaban" class="gt_row gt_right">NA</td>
<td headers="stub_1_12 Lisinopril" class="gt_row gt_right">1633 (12.5%)</td>
<td headers="stub_1_12 Rivaroxaban" class="gt_row gt_right">433 (14.6%)</td>
<td headers="stub_1_12 Warfarin" class="gt_row gt_right">1097 (13.5%)</td></tr>
    <tr><th id="stub_1_13" scope="row" class="gt_row gt_left gt_stub">Region: Northeast</th>
<td headers="stub_1_13 Apixaban" class="gt_row gt_right">589 (22%)</td>
<td headers="stub_1_13 Dabigatran" class="gt_row gt_right">194 (24.5%)</td>
<td headers="stub_1_13 Edoxaban" class="gt_row gt_right">1 (16.7%)</td>
<td headers="stub_1_13 Lisinopril" class="gt_row gt_right">2233 (17.2%)</td>
<td headers="stub_1_13 Rivaroxaban" class="gt_row gt_right">640 (21.6%)</td>
<td headers="stub_1_13 Warfarin" class="gt_row gt_right">1734 (21.3%)</td></tr>
    <tr><th id="stub_1_14" scope="row" class="gt_row gt_left gt_stub">Region: North Central</th>
<td headers="stub_1_14 Apixaban" class="gt_row gt_right">938 (35%)</td>
<td headers="stub_1_14 Dabigatran" class="gt_row gt_right">235 (29.7%)</td>
<td headers="stub_1_14 Edoxaban" class="gt_row gt_right">3 (50%)</td>
<td headers="stub_1_14 Lisinopril" class="gt_row gt_right">4523 (34.8%)</td>
<td headers="stub_1_14 Rivaroxaban" class="gt_row gt_right">909 (30.7%)</td>
<td headers="stub_1_14 Warfarin" class="gt_row gt_right">2700 (33.1%)</td></tr>
    <tr><th id="stub_1_15" scope="row" class="gt_row gt_left gt_stub">Region: South</th>
<td headers="stub_1_15 Apixaban" class="gt_row gt_right">925 (34.6%)</td>
<td headers="stub_1_15 Dabigatran" class="gt_row gt_right">261 (33%)</td>
<td headers="stub_1_15 Edoxaban" class="gt_row gt_right">1 (16.7%)</td>
<td headers="stub_1_15 Lisinopril" class="gt_row gt_right">4611 (35.4%)</td>
<td headers="stub_1_15 Rivaroxaban" class="gt_row gt_right">1115 (37.6%)</td>
<td headers="stub_1_15 Warfarin" class="gt_row gt_right">2522 (31%)</td></tr>
    <tr><th id="stub_1_16" scope="row" class="gt_row gt_left gt_stub">Region: West</th>
<td headers="stub_1_16 Apixaban" class="gt_row gt_right">222 (8.3%)</td>
<td headers="stub_1_16 Dabigatran" class="gt_row gt_right">99 (12.5%)</td>
<td headers="stub_1_16 Edoxaban" class="gt_row gt_right">1 (16.7%)</td>
<td headers="stub_1_16 Lisinopril" class="gt_row gt_right">1524 (11.7%)</td>
<td headers="stub_1_16 Rivaroxaban" class="gt_row gt_right">278 (9.4%)</td>
<td headers="stub_1_16 Warfarin" class="gt_row gt_right">1092 (13.4%)</td></tr>
    <tr><th id="stub_1_17" scope="row" class="gt_row gt_left gt_stub">Region: Unknown</th>
<td headers="stub_1_17 Apixaban" class="gt_row gt_right">3 (0.1%)</td>
<td headers="stub_1_17 Dabigatran" class="gt_row gt_right">2 (0.3%)</td>
<td headers="stub_1_17 Edoxaban" class="gt_row gt_right">NA</td>
<td headers="stub_1_17 Lisinopril" class="gt_row gt_right">114 (0.9%)</td>
<td headers="stub_1_17 Rivaroxaban" class="gt_row gt_right">21 (0.7%)</td>
<td headers="stub_1_17 Warfarin" class="gt_row gt_right">93 (1.1%)</td></tr>
    <tr><th id="stub_1_18" scope="row" class="gt_row gt_left gt_stub">Region: NA</th>
<td headers="stub_1_18 Apixaban" class="gt_row gt_right">NA</td>
<td headers="stub_1_18 Dabigatran" class="gt_row gt_right">NA</td>
<td headers="stub_1_18 Edoxaban" class="gt_row gt_right">NA</td>
<td headers="stub_1_18 Lisinopril" class="gt_row gt_right">9 (0.1%)</td>
<td headers="stub_1_18 Rivaroxaban" class="gt_row gt_right">1 (0%)</td>
<td headers="stub_1_18 Warfarin" class="gt_row gt_right">7 (0.1%)</td></tr>
    <tr><th id="stub_1_19" scope="row" class="gt_row gt_left gt_stub">Plan Type: Comprehensive</th>
<td headers="stub_1_19 Apixaban" class="gt_row gt_right">714 (26.7%)</td>
<td headers="stub_1_19 Dabigatran" class="gt_row gt_right">347 (43.9%)</td>
<td headers="stub_1_19 Edoxaban" class="gt_row gt_right">1 (16.7%)</td>
<td headers="stub_1_19 Lisinopril" class="gt_row gt_right">3386 (26%)</td>
<td headers="stub_1_19 Rivaroxaban" class="gt_row gt_right">874 (29.5%)</td>
<td headers="stub_1_19 Warfarin" class="gt_row gt_right">2143 (26.3%)</td></tr>
    <tr><th id="stub_1_20" scope="row" class="gt_row gt_left gt_stub">Plan Type: EPO</th>
<td headers="stub_1_20 Apixaban" class="gt_row gt_right">11 (0.4%)</td>
<td headers="stub_1_20 Dabigatran" class="gt_row gt_right">3 (0.4%)</td>
<td headers="stub_1_20 Edoxaban" class="gt_row gt_right">NA</td>
<td headers="stub_1_20 Lisinopril" class="gt_row gt_right">65 (0.5%)</td>
<td headers="stub_1_20 Rivaroxaban" class="gt_row gt_right">12 (0.4%)</td>
<td headers="stub_1_20 Warfarin" class="gt_row gt_right">37 (0.5%)</td></tr>
    <tr><th id="stub_1_21" scope="row" class="gt_row gt_left gt_stub">Plan Type: HMO</th>
<td headers="stub_1_21 Apixaban" class="gt_row gt_right">301 (11.2%)</td>
<td headers="stub_1_21 Dabigatran" class="gt_row gt_right">58 (7.3%)</td>
<td headers="stub_1_21 Edoxaban" class="gt_row gt_right">NA</td>
<td headers="stub_1_21 Lisinopril" class="gt_row gt_right">1687 (13%)</td>
<td headers="stub_1_21 Rivaroxaban" class="gt_row gt_right">287 (9.7%)</td>
<td headers="stub_1_21 Warfarin" class="gt_row gt_right">1222 (15%)</td></tr>
    <tr><th id="stub_1_22" scope="row" class="gt_row gt_left gt_stub">Plan Type: POS</th>
<td headers="stub_1_22 Apixaban" class="gt_row gt_right">87 (3.2%)</td>
<td headers="stub_1_22 Dabigatran" class="gt_row gt_right">31 (3.9%)</td>
<td headers="stub_1_22 Edoxaban" class="gt_row gt_right">NA</td>
<td headers="stub_1_22 Lisinopril" class="gt_row gt_right">631 (4.8%)</td>
<td headers="stub_1_22 Rivaroxaban" class="gt_row gt_right">137 (4.6%)</td>
<td headers="stub_1_22 Warfarin" class="gt_row gt_right">360 (4.4%)</td></tr>
    <tr><th id="stub_1_23" scope="row" class="gt_row gt_left gt_stub">Plan Type: PPO</th>
<td headers="stub_1_23 Apixaban" class="gt_row gt_right">1308 (48.9%)</td>
<td headers="stub_1_23 Dabigatran" class="gt_row gt_right">326 (41.2%)</td>
<td headers="stub_1_23 Edoxaban" class="gt_row gt_right">1 (16.7%)</td>
<td headers="stub_1_23 Lisinopril" class="gt_row gt_right">6035 (46.4%)</td>
<td headers="stub_1_23 Rivaroxaban" class="gt_row gt_right">1395 (47.1%)</td>
<td headers="stub_1_23 Warfarin" class="gt_row gt_right">3728 (45.8%)</td></tr>
    <tr><th id="stub_1_24" scope="row" class="gt_row gt_left gt_stub">Plan Type: POS with capitation</th>
<td headers="stub_1_24 Apixaban" class="gt_row gt_right">29 (1.1%)</td>
<td headers="stub_1_24 Dabigatran" class="gt_row gt_right">3 (0.4%)</td>
<td headers="stub_1_24 Edoxaban" class="gt_row gt_right">NA</td>
<td headers="stub_1_24 Lisinopril" class="gt_row gt_right">70 (0.5%)</td>
<td headers="stub_1_24 Rivaroxaban" class="gt_row gt_right">28 (0.9%)</td>
<td headers="stub_1_24 Warfarin" class="gt_row gt_right">39 (0.5%)</td></tr>
    <tr><th id="stub_1_25" scope="row" class="gt_row gt_left gt_stub">Plan Type: CDHP</th>
<td headers="stub_1_25 Apixaban" class="gt_row gt_right">82 (3.1%)</td>
<td headers="stub_1_25 Dabigatran" class="gt_row gt_right">7 (0.9%)</td>
<td headers="stub_1_25 Edoxaban" class="gt_row gt_right">1 (16.7%)</td>
<td headers="stub_1_25 Lisinopril" class="gt_row gt_right">477 (3.7%)</td>
<td headers="stub_1_25 Rivaroxaban" class="gt_row gt_right">97 (3.3%)</td>
<td headers="stub_1_25 Warfarin" class="gt_row gt_right">221 (2.7%)</td></tr>
    <tr><th id="stub_1_26" scope="row" class="gt_row gt_left gt_stub">Plan Type: HDHP</th>
<td headers="stub_1_26 Apixaban" class="gt_row gt_right">60 (2.2%)</td>
<td headers="stub_1_26 Dabigatran" class="gt_row gt_right">5 (0.6%)</td>
<td headers="stub_1_26 Edoxaban" class="gt_row gt_right">3 (50%)</td>
<td headers="stub_1_26 Lisinopril" class="gt_row gt_right">265 (2%)</td>
<td headers="stub_1_26 Rivaroxaban" class="gt_row gt_right">70 (2.4%)</td>
<td headers="stub_1_26 Warfarin" class="gt_row gt_right">110 (1.4%)</td></tr>
    <tr><th id="stub_1_27" scope="row" class="gt_row gt_left gt_stub">Plan Type: NA</th>
<td headers="stub_1_27 Apixaban" class="gt_row gt_right">86 (3.2%)</td>
<td headers="stub_1_27 Dabigatran" class="gt_row gt_right">11 (1.4%)</td>
<td headers="stub_1_27 Edoxaban" class="gt_row gt_right">NA</td>
<td headers="stub_1_27 Lisinopril" class="gt_row gt_right">412 (3.2%)</td>
<td headers="stub_1_27 Rivaroxaban" class="gt_row gt_right">67 (2.3%)</td>
<td headers="stub_1_27 Warfarin" class="gt_row gt_right">296 (3.6%)</td></tr>
    <tr><th id="stub_1_28" scope="row" class="gt_row gt_left gt_stub">Mean HAS-BLED Score</th>
<td headers="stub_1_28 Apixaban" class="gt_row gt_right">2.26</td>
<td headers="stub_1_28 Dabigatran" class="gt_row gt_right">1.79</td>
<td headers="stub_1_28 Edoxaban" class="gt_row gt_right">1.83</td>
<td headers="stub_1_28 Lisinopril" class="gt_row gt_right">1.75</td>
<td headers="stub_1_28 Rivaroxaban" class="gt_row gt_right">2.06</td>
<td headers="stub_1_28 Warfarin" class="gt_row gt_right">2.19</td></tr>
    <tr><th id="stub_1_29" scope="row" class="gt_row gt_left gt_stub">HAS-BLED: Hypertension</th>
<td headers="stub_1_29 Apixaban" class="gt_row gt_right">2056 (76.8%)</td>
<td headers="stub_1_29 Dabigatran" class="gt_row gt_right">518 (65.5%)</td>
<td headers="stub_1_29 Edoxaban" class="gt_row gt_right">3 (50%)</td>
<td headers="stub_1_29 Lisinopril" class="gt_row gt_right">8193 (63%)</td>
<td headers="stub_1_29 Rivaroxaban" class="gt_row gt_right">2124 (71.7%)</td>
<td headers="stub_1_29 Warfarin" class="gt_row gt_right">5348 (65.6%)</td></tr>
    <tr><th id="stub_1_30" scope="row" class="gt_row gt_left gt_stub">HAS-BLED: Liver Dysfunction</th>
<td headers="stub_1_30 Apixaban" class="gt_row gt_right">193 (7.2%)</td>
<td headers="stub_1_30 Dabigatran" class="gt_row gt_right">11 (1.4%)</td>
<td headers="stub_1_30 Edoxaban" class="gt_row gt_right">1 (16.7%)</td>
<td headers="stub_1_30 Lisinopril" class="gt_row gt_right">428 (3.3%)</td>
<td headers="stub_1_30 Rivaroxaban" class="gt_row gt_right">148 (5%)</td>
<td headers="stub_1_30 Warfarin" class="gt_row gt_right">325 (4%)</td></tr>
    <tr><th id="stub_1_31" scope="row" class="gt_row gt_left gt_stub">HAS-BLED: Kidney Dysfunction</th>
<td headers="stub_1_31 Apixaban" class="gt_row gt_right">599 (22.4%)</td>
<td headers="stub_1_31 Dabigatran" class="gt_row gt_right">118 (14.9%)</td>
<td headers="stub_1_31 Edoxaban" class="gt_row gt_right">0 (0%)</td>
<td headers="stub_1_31 Lisinopril" class="gt_row gt_right">1444 (11.1%)</td>
<td headers="stub_1_31 Rivaroxaban" class="gt_row gt_right">357 (12%)</td>
<td headers="stub_1_31 Warfarin" class="gt_row gt_right">1555 (19.1%)</td></tr>
    <tr><th id="stub_1_32" scope="row" class="gt_row gt_left gt_stub">HAS-BLED: Stroke</th>
<td headers="stub_1_32 Apixaban" class="gt_row gt_right">489 (18.3%)</td>
<td headers="stub_1_32 Dabigatran" class="gt_row gt_right">113 (14.3%)</td>
<td headers="stub_1_32 Edoxaban" class="gt_row gt_right">3 (50%)</td>
<td headers="stub_1_32 Lisinopril" class="gt_row gt_right">1413 (10.9%)</td>
<td headers="stub_1_32 Rivaroxaban" class="gt_row gt_right">672 (22.7%)</td>
<td headers="stub_1_32 Warfarin" class="gt_row gt_right">2289 (28.1%)</td></tr>
    <tr><th id="stub_1_33" scope="row" class="gt_row gt_left gt_stub">HAS-BLED: Bleeding Predisposition</th>
<td headers="stub_1_33 Apixaban" class="gt_row gt_right">1014 (37.9%)</td>
<td headers="stub_1_33 Dabigatran" class="gt_row gt_right">163 (20.6%)</td>
<td headers="stub_1_33 Edoxaban" class="gt_row gt_right">1 (16.7%)</td>
<td headers="stub_1_33 Lisinopril" class="gt_row gt_right">3140 (24.1%)</td>
<td headers="stub_1_33 Rivaroxaban" class="gt_row gt_right">864 (29.1%)</td>
<td headers="stub_1_33 Warfarin" class="gt_row gt_right">2917 (35.8%)</td></tr>
    <tr><th id="stub_1_34" scope="row" class="gt_row gt_left gt_stub">HAS-BLED: Alcohol Use</th>
<td headers="stub_1_34 Apixaban" class="gt_row gt_right">60 (2.2%)</td>
<td headers="stub_1_34 Dabigatran" class="gt_row gt_right">10 (1.3%)</td>
<td headers="stub_1_34 Edoxaban" class="gt_row gt_right">0 (0%)</td>
<td headers="stub_1_34 Lisinopril" class="gt_row gt_right">336 (2.6%)</td>
<td headers="stub_1_34 Rivaroxaban" class="gt_row gt_right">61 (2.1%)</td>
<td headers="stub_1_34 Warfarin" class="gt_row gt_right">193 (2.4%)</td></tr>
    <tr><th id="stub_1_35" scope="row" class="gt_row gt_left gt_stub">Prior NSAID use (183 days)</th>
<td headers="stub_1_35 Apixaban" class="gt_row gt_right">374 (14%)</td>
<td headers="stub_1_35 Dabigatran" class="gt_row gt_right">101 (12.8%)</td>
<td headers="stub_1_35 Edoxaban" class="gt_row gt_right">0 (0%)</td>
<td headers="stub_1_35 Lisinopril" class="gt_row gt_right">1819 (14%)</td>
<td headers="stub_1_35 Rivaroxaban" class="gt_row gt_right">474 (16%)</td>
<td headers="stub_1_35 Warfarin" class="gt_row gt_right">1203 (14.8%)</td></tr>
    <tr><th id="stub_1_36" scope="row" class="gt_row gt_left gt_stub">Prior antiplatelet use (183 days)</th>
<td headers="stub_1_36 Apixaban" class="gt_row gt_right">496 (18.5%)</td>
<td headers="stub_1_36 Dabigatran" class="gt_row gt_right">159 (20.1%)</td>
<td headers="stub_1_36 Edoxaban" class="gt_row gt_right">1 (16.7%)</td>
<td headers="stub_1_36 Lisinopril" class="gt_row gt_right">1709 (13.1%)</td>
<td headers="stub_1_36 Rivaroxaban" class="gt_row gt_right">509 (17.2%)</td>
<td headers="stub_1_36 Warfarin" class="gt_row gt_right">1234 (15.1%)</td></tr>
    <tr><th id="stub_1_37" scope="row" class="gt_row gt_left gt_stub">Prior parenteral anticoagulant use (183 days)</th>
<td headers="stub_1_37 Apixaban" class="gt_row gt_right">64 (2.4%)</td>
<td headers="stub_1_37 Dabigatran" class="gt_row gt_right">21 (2.7%)</td>
<td headers="stub_1_37 Edoxaban" class="gt_row gt_right">2 (33.3%)</td>
<td headers="stub_1_37 Lisinopril" class="gt_row gt_right">244 (1.9%)</td>
<td headers="stub_1_37 Rivaroxaban" class="gt_row gt_right">135 (4.6%)</td>
<td headers="stub_1_37 Warfarin" class="gt_row gt_right">468 (5.7%)</td></tr>
    <tr><th id="stub_1_38" scope="row" class="gt_row gt_left gt_stub">Prior SSRI/SNRI use (183 days)</th>
<td headers="stub_1_38 Apixaban" class="gt_row gt_right">420 (15.7%)</td>
<td headers="stub_1_38 Dabigatran" class="gt_row gt_right">72 (9.1%)</td>
<td headers="stub_1_38 Edoxaban" class="gt_row gt_right">0 (0%)</td>
<td headers="stub_1_38 Lisinopril" class="gt_row gt_right">1651 (12.7%)</td>
<td headers="stub_1_38 Rivaroxaban" class="gt_row gt_right">437 (14.7%)</td>
<td headers="stub_1_38 Warfarin" class="gt_row gt_right">1228 (15.1%)</td></tr>
    <tr><th id="stub_1_39" scope="row" class="gt_row gt_left gt_stub">Prior GI protectant use (183 days)</th>
<td headers="stub_1_39 Apixaban" class="gt_row gt_right">878 (32.8%)</td>
<td headers="stub_1_39 Dabigatran" class="gt_row gt_right">201 (25.4%)</td>
<td headers="stub_1_39 Edoxaban" class="gt_row gt_right">2 (33.3%)</td>
<td headers="stub_1_39 Lisinopril" class="gt_row gt_right">3069 (23.6%)</td>
<td headers="stub_1_39 Rivaroxaban" class="gt_row gt_right">935 (31.5%)</td>
<td headers="stub_1_39 Warfarin" class="gt_row gt_right">2336 (28.7%)</td></tr>
  </tbody>
  <tfoot>
    <tr class="gt_sourcenotes">
      <td class="gt_sourcenote" colspan="7">Note: Values are reported as n (%), Mean (SD), or as indicated.</td>
    </tr>
  </tfoot>
</table>
</div>
</body>
</html>
